



Additional Resources

General Resources for Clinical Investigations Involving Drugs

- From ORRP:
 - Investigator Guidance: <https://orrrp.osu.edu/irb/investigator-guidance/>
 - HRPP Policy: Research Involving Investigational Drugs: <http://orrrp.osu.edu/files/2012/02/Research-Involving-Investigational-Drugs.pdf>
 - Past ORRP Educational Sessions: <http://orrrp.osu.edu/irb/workshopsseminars/orrpeducation/>
- From FDA:
 - Clinical Trials & Human Subject Protection: <https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection>
 - Drug Guidance Documents: <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>
 - FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency>
- Others:
 - ReGARDD: Regulatory Guidance for Academic Research of Drugs and Devices: <http://www.regardd.org>

Drug Information: Product labeling & classification

- Databases of approved drugs and biologics:
 - DailyMed drug label database: <https://dailymed.nlm.nih.gov/dailymed/>
 - FDA's Approved Drug Databases (includes link to Biologics database): <https://www.fda.gov/drugs/drug-approvals-and-databases/resources-information-approved-drugs>
- Drug classification & product jurisdiction
 - Biologics Product Jurisdiction: <https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/cber-product-jurisdiction>
 - Combination Products: <https://www.fda.gov/combination-products>
 - Draft guidance: Requesting FDA Feedback on Combination Products: <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/replies-inquiries-fda-good-clinical-practice>
 - Guidance: Classification of Products as Drugs and Devices & Additional Product Classification Issues: <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/replies-inquiries-fda-good-clinical-practice>

Investigational New Drug Applications (INDs) & IND Exemptions

- From FDA:
 - General IND page: <https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application>
 - Investigator Initiated IND Applications: <https://www.fda.gov/drugs/investigational-new-drug-ind-application/investigator-initiated-investigational-new-drug-ind-applications>
 - FDA Guidance: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND: <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM229175.pdf>
 - FDA Guidance: IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-exemptions-studies-lawfully-marketed-drug-or-biological-products-treatment-cancer>
- Ohio State Resources
 - Center for Clinical and Translational Science (CCTS) IND/IDE support: <https://ccts.osu.edu/content/indide-support>
- Other Resources
 - ReGARDD's Initial IND Submission information (templates, info, and video walk-through): <http://regardd.org/drugs/initial-ind-submission>
 - UNC/ReGARDD IND Workshop (3 hours): <https://panopto-web.med.unc.edu/Panopto/Pages/Viewer.aspx?id=0d8208a7-e853-4d55-a5a7-ac1d8e80f2d3>

IRB Application Resources

- General Buck-IRB information: <http://orpp.osu.edu/irb/buck-irb>
- Submissions to Western IRB (WIRB): <http://orpp.osu.edu/irb/osuirbpolicies/wirb/>
- Submissions to NCI Central IRB (CIRB): <http://orpp.osu.edu/irb/osuirbpolicies/nci-central-irb/>
- Recorded education sessions: <http://orpp.osu.edu/irb/workshopsseminars/orrpeducation/>
 - “Buck-IRB and Initial IRB Submissions – medical focus” (March 2019)
 - “Amendments and Buck-IRB” (December 2019)
 - “Event Reporting in Human Subjects Research” (June 2020)

FDA Inspections & Audits

- ORRP guidance for investigators/research staff: <http://orpp.osu.edu/irb/investigator-guidance/fda-inspections/>
- FDA's Biomonitoring Program (BIMO): <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/bioresearch-monitoring-program-bimo>

FDA Divisions Relevant to Drug Research & Contact Information

- Center for Drug Evaluation and Research (CDER) Offices & Divisions: <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-offices-and-divisions>
- Center for Biologics Evaluation and Research (CBER): <https://www.fda.gov/about-fda/fda-organization/center-biologics-evaluation-and-research-cber>
- IND/IDE Contacts (general): <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/indide-contacts>